lanraplenib
Small moleculeexperimental
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2016 (NCT02885181)
Timeline
Indications
Mechanism of action
- Tyrosine-protein kinase SYKINHIBITOR
SYK inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Nc1cncc(-c2cn3ccnc3c(Nc3ccc(N4CCN(C5COC5)CC4)cc3)n2)n1- Mol. weight
- 443.52 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3986824 ↗
Also known as
- gs-9876
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05028751 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2021 | Kronos Bio |
| NCT03285711 | Phase 2 | Oct 6, 2017 | Gilead Sciences |
| NCT03134222 | Phase 2 | May 24, 2017 | Galapagos NV, Gilead Sciences |
| NCT02959138 | Phase 1 | Nov 21, 2016 | Gilead Sciences |
| NCT02885181 | Phase 2 | Sep 1, 2016 | Gilead Sciences |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Gilead Sciences | For profit | 4 | 4 | 2 | 2016 |
| Galapagos NV | For profit | 1 | 0 | 1 | 2017 |
| Kronos Bio | For profit | 1 | 1 | 1 | 2021 |
3 organizations
Page 1 / 1